Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 at JPMorgan Chase & Co.

Travere Therapeutics (NASDAQ:TVTX) had its target price boosted by JPMorgan Chase & Co. from $42.00 to $44.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also recently commented on TVTX. Scotiabank boosted their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. Barclays boosted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. HC Wainwright boosted their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, Evercore ISI boosted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $30.62.

Travere Therapeutics Trading Up 1.8 %

NASDAQ TVTX opened at $21.03 on Wednesday. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -5.13 and a beta of 0.72. The firm’s 50 day moving average price is $19.90 and its two-hundred day moving average price is $16.89.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $74.79 million for the quarter, compared to analysts’ expectations of $72.38 million. Equities analysts anticipate that Travere Therapeutics will post -1.4 EPS for the current year.

Insider Activity

In related news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric M. Dube sold 11,375 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the transaction, the chief executive officer now directly owns 419,173 shares of the company’s stock, valued at $10,076,918.92. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 206,335 shares of company stock valued at $4,453,012. Insiders own 4.06% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TVTX. Driehaus Capital Management LLC raised its position in Travere Therapeutics by 608.1% in the fourth quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company’s stock worth $38,637,000 after purchasing an additional 1,904,733 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Travere Therapeutics during the fourth quarter worth about $21,075,000. RA Capital Management L.P. bought a new stake in Travere Therapeutics during the fourth quarter worth about $20,033,000. Jennison Associates LLC acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth approximately $14,222,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Travere Therapeutics by 36.7% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company’s stock valued at $37,875,000 after acquiring an additional 583,836 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.